UCB SA (OTCMKTS:UCBJF – Get Free Report) reached a new 52-week high on Thursday . The stock traded as high as $184.00 and last traded at $184.00, with a volume of 0 shares trading hands. The stock had previously closed at $184.00.
UCB Price Performance
The firm has a 50 day moving average of $179.31 and a two-hundred day moving average of $152.90. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Where Do I Find 52-Week Highs and Lows?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- The 3 Best Retail Stocks to Shop for in August
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
